Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply

John T. Wilkins; Donald M. Lloyd-Jones

doi:10.1001/jama.2021.17980

Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply

John T. Wilkins, Donald M. Lloyd-Jones^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2205-2206
Number of pages	2
Journal	JAMA
Volume	326
Issue number	21
DOIs	https://doi.org/10.1001/jama.2021.17980
State	Published - Dec 7 2021

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.2021.17980

Cite this

@article{75a453a64f7e4b9e811c62d842fa0f6c,

title = "Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply",

author = "Wilkins, {John T.} and Lloyd-Jones, {Donald M.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Wilkins reported receiving grants from the National Institutes of Health during the conduct of the study and consulting fees from NGM Biopharmaceuticals and 3M. Dr Lloyd-Jones reported receiving grants from the National Institutes of Health during the conduct of the study. Funding Information: Conflict of Interest Disclosures: Dr Ray reported receiving support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and that his institution (Imperial College London) receives support from the NIHR Applied Research Collaboration Northwest London. Dr Ray also reported receiving lecture fees from Kowa, Lupin, and Zuelling Pharma; grant support (paid to his institution), lecture fees, and advisory board fees from Amgen, Regeneron Pharmaceuticals/Sanofi, Daiichi Sankyo, and Pfizer; lecture fees and fees for serving on steering committees for trials from AstraZeneca and Eli Lilly; fees for serving on steering committees for trials from the Medicines Company and Esperion; advisory board fees from Abbott, Akcea Therapeutics, Novartis, Silence Therapeutics, Bayer, and Daiichi Sankyo; lecture fees and advisory board fees from Novo Nordisk and Boehringer Ingelheim; grant support and advisory board fees from Merck Sharp & Dohme; and fees for serving as principal investigator for a trial from Resverlogix. Dr Wright reported receiving advisory board fees from Boehringer Ingelheim and past fees for consulting on lipid issues from the Medicines Company. Funding/Support: Editorial support in the writing of this letter was funded by Novartis Pharma AG, Basel, Switzerland. Role of the Funder/Sponsor: Novartis Pharma AG had no role in the preparation of the manuscript or decision to submit the manuscript for publication. Novartis reviewed the manuscript (with no suggested changes) but did not have a right to reject the version submitted.",

year = "2021",

month = dec,

day = "7",

doi = "10.1001/jama.2021.17980",

language = "English (US)",

volume = "326",

pages = "2205--2206",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "21",

}

TY - JOUR

T1 - Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply

AU - Wilkins, John T.

AU - Lloyd-Jones, Donald M.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Wilkins reported receiving grants from the National Institutes of Health during the conduct of the study and consulting fees from NGM Biopharmaceuticals and 3M. Dr Lloyd-Jones reported receiving grants from the National Institutes of Health during the conduct of the study. Funding Information: Conflict of Interest Disclosures: Dr Ray reported receiving support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and that his institution (Imperial College London) receives support from the NIHR Applied Research Collaboration Northwest London. Dr Ray also reported receiving lecture fees from Kowa, Lupin, and Zuelling Pharma; grant support (paid to his institution), lecture fees, and advisory board fees from Amgen, Regeneron Pharmaceuticals/Sanofi, Daiichi Sankyo, and Pfizer; lecture fees and fees for serving on steering committees for trials from AstraZeneca and Eli Lilly; fees for serving on steering committees for trials from the Medicines Company and Esperion; advisory board fees from Abbott, Akcea Therapeutics, Novartis, Silence Therapeutics, Bayer, and Daiichi Sankyo; lecture fees and advisory board fees from Novo Nordisk and Boehringer Ingelheim; grant support and advisory board fees from Merck Sharp & Dohme; and fees for serving as principal investigator for a trial from Resverlogix. Dr Wright reported receiving advisory board fees from Boehringer Ingelheim and past fees for consulting on lipid issues from the Medicines Company. Funding/Support: Editorial support in the writing of this letter was funded by Novartis Pharma AG, Basel, Switzerland. Role of the Funder/Sponsor: Novartis Pharma AG had no role in the preparation of the manuscript or decision to submit the manuscript for publication. Novartis reviewed the manuscript (with no suggested changes) but did not have a right to reject the version submitted.

PY - 2021/12/7

Y1 - 2021/12/7

UR - http://www.scopus.com/inward/record.url?scp=85121231223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121231223&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.17980

DO - 10.1001/jama.2021.17980

M3 - Letter

C2 - 34874422

AN - SCOPUS:85121231223

SN - 0098-7484

VL - 326

SP - 2205

EP - 2206

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 21

ER -

Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this